You're using an outdated browser. Please upgrade to a modern browser for the best experience.
Molecular Basis of FIX Deficiency in Hemophilia B: Comparison
View Latest Version
Please note this is a comparison between Version 2 by Bruce Ren and Version 3 by Bruce Ren.

Hemophilia is an X-linked recessive bleeding disorder caused by a deficiency of coagulation factor VIII (FVIII) or factor IX (FIX), which are named hemophilia A (OMIM#306700) and hemophilia B (OMIM#306900), respectively. Coagulation factor IX (FIX) is a vitamin K dependent protein and its deficiency causes hemophilia B, an X-linked recessive bleeding disorder. More than 1000 mutations in the F9 gene have been identified in hemophilia B patients. Hemophilia is an X-linked recessive bleeding disorder caused by a deficiency of coagulation factor VIII (FVIII) or factor IX (FIX), which are named hemophilia A (OMIM#306700) and hemophilia B (OMIM#306900), respectively. Because the genes of FVIII and FIX are located in chromosome X, hemophilia has historically been considered as a “male disease".

  • hemophilia B
  • coagulation factor IX
  • molecular mechanism
  • γ-carboxylation
  • vitamin K-dependent proteins
  • point mutation
  • missense mutation
  • aberrant splicing
  • vitamin K
  • coagulation factor VIII

1. Introduction

Hemophilia is an X-linked recessive bleeding disorder caused by a deficiency of coagulation factor VIII (FVIII) or factor IX (FIX), which are named hemophilia A (OMIM#306700) and hemophilia B (OMIM#306900), respectively. Because the genes of FVIII and FIX are located in chromosome X, hemophilia has historically been considered as a “male disease” [1]. The first hemophilia B patient, Stephen Christmas, was reported in 1952, hence hemophilia B is also called Christmas disease [2]. Compared with hemophilia A, hemophilia B is much less common and is estimated to account for 15–20% of all hemophilia cases [3]. In addition, hemophilia B is often considered less severe than hemophilia A. The prevalence of hemophilia B is about 1 in 30,000 male live births [4]. The disease severity of hemophilia B correlates with patients’ plasma level of FIX:C. Based on the FIX:C level, hemophilia B has been classified into different severities [5]. The normal level of FIX:C is 1 IU/mL in the blood plasma. Patients with <1% of normal FIX:C (<0.01 IU/mL) are defined as severe hemophilia cases and frequent occurrences of spontaneous bleeding are observed [6]. Moderate cases are patients with 1–5% (0.01–0.05 IU/mL) of normal FIX:C, and they experience bleeding primarily after injury [6]. Those with 5–40% normal FIX:C (0.05–0.40 IU/mL) are considered as mild cases, and they usually experience bleeding only with surgery or major trauma [6].
The clinical phenotype of hemophilia B, however, does not always follow these severity classifications measured from FIX:C [7]. In addition, it remains unclear why patients carrying the same mutation in some cases exhibit different bleeding tendencies that vary from mild to severe [8]. Unveiling the molecular mechanism of hemophilia B will help to understand the heterogeneity of the phenotype and provide significant insights for patient diagnosis and treatment. The enormous number of mutations identified in hemophilia B suggests that its molecular basis is extremely diverse [8][9]. 

2. The Gene of FIX

The gene of FIX, named F9, was cloned in 1982 [10][11]. With the use of molecular genetic linkage analysis, F9 was identified as the pathogenic gene of hemophilia B. The FIX gene spans 34 kb on the long arm of X chromosome at band Xq27.1 and consists of eight exons and seven introns [12][13] (Figure 1). The eight exons transcribe into a 2.8 kb mRNA (NM_000133) with a 1.4 kb noncoding region at the 3′ end [14]. The open reading frame (ORF) of the F9 mRNA encodes a precursor protein containing 461 amino acids (aa), which include a N-terminal signal peptide (1–28 aa) and an 18-residue propeptide (29–46 aa), followed by a 415-residue mature protein that is further divided into a Gla domain (47–92 aa), two epidermal growth factor (EGF) like domains (93–171 aa), a linker sequence (172–191 aa), an activation peptide (AP, 192–226 aa), and a serine protease (SP) domain (227–461 aa) [8] (Figure 1). Exon 1 encodes a typical signal peptide designated for protein secretion from hepatocytes, exon 2 encodes the propeptide sequence and the Gla domain, exon 3 encodes the final part of the Gla domain and a short hydrophobic helical stack, exons 4 and 5 encode the two EGF-like domains, exon 6 encodes the activation peptide, and exons 7 and 8 encode the catalytic SP domain [15].
Figure 1. Schematic diagram of the F9 gene structure and FIX protein processing. The F9 gene contains eight exons and seven introns that transcribe into a 2.8 kb mRNA with 5′ and 3′ noncoding flanking sequence. The coding sequence translates into the FIX precursor, including the signal peptide, propeptide, Gla domain, EGF1 domain, EGF2 domain, linker, activation peptide (AP), and serine protease (SP) domain. The FIX precursor undergoes multiple post-translational modifications, especially γ-carboxylation, and is further processed to form the mature FIX secreted to the extracellular space. The inactive FIX zymogen is activated by the cleavage of the activation peptide to FIXa, which contains a light chain and a heavy chain linked by a disulfide bond.

3. Mechanisms of FIX Deficiency

F9 mutations lead to FIX deficiency at multiple levels, including its gene structure, gene transcription, splicing, translation, posttranslational modifications, protein folding, and formation of functional complex [8][16][17][18][19][20][21][22]. In the F9 variants database, about 88% of patients carry point mutations, and only about 12% have deletions, insertions, duplications, or indels (Table 1 and Table 2). Most deletions, insertions, duplications, and indels in the coding sequence cause a frame shift [16] that generates a truncated or an extended polypeptide with a changed sequence. A small portion of these mutations lead to the inframe effect, which has a deletion or (and) insertion with multiples of three nucleotides. Most patients with frame shift and inframe mutations show severe hemophilia B [16]. In the introns, deletions, indels, and insertions usually cause aberrant splicing, leading to severe hemophilia B in almost all of the affected patients [16]. About 2% of unique mutations affect multiple regions of the F9 gene, and correspond to gross deletions of the F9 gene, which also lead to severe hemophilia B. Additionally, it is worth noting that individuals with gross deletions have the highest risk (43%) of inhibitor development [9].
Table 1. Statistics of mutations in the F9 database.
Regions MTs UMs % of UMs PN % of PN
Noncoding Promoter * Point
Table 2. Statistics of point mutations in the F9 gene.
Regions Mutation Effects Unique Mutations Patient Number % of Total Patients
23
Promoter Leyden/NA2.10 86 2.32
23 86 2.32   Deletion 2 0.18 2 0.05
  Polymorphism 5 0.46 5 0.13
Intron Point 86 7.86 226 6.09
  Deletion 14 1.28 23 0.62
  Insertion 2 0.18 8 0.22
  Indel 1
 
Duplication
Exons Missense 586 2422 65.231 0.09 1 0.03
  Nonsense 87 469 12.63  Silent    
0.13
16 46 1.24
Introns Splice 86 226 6.09
3′ UTR NA 2 22 0.59 0.09 1 0.03
  Polymorphism 33 Polymorphism 2 0.18 3 0.08
Coding
Grand total  
Grand total   3.02 33 0.89
3′ UTR Point 2 0.18 22 0.59 1094 100 3713 100
800
3271
88.1
 
Point
689 62.98 2937 79.10
Deletion 145 13.25 204 5.49
Insertion 33 3.02 38 1.02
Indel 15 1.37 17 0.46
Duplication 4 0.37 4 0.11
  Polymorphism 11 1.01 18 0.48
Multiple Regions   Deletion 19 1.75 78 2.10
Insertion 1 0.09 1 0.03
  Indel 1 0.09 1 0.03
Complex 5 0.46 5
For hemophilia B patients with point mutations, their bleeding phenotypes vary from severe to mild, and there are multiple mechanisms causing FIX deficiency [8][17][21][22]. Generally, point mutations in the promoter region result in hemophilia B Leyden [9], those in the exons cause missense, nonsense, or silent mutations, and those in introns cause aberrant splicing [16]. the researchers will focus on the pathogenic mechanisms of point mutations in the following sections.

3.1. Point Mutations in Noncoding Region

3.1.1. Mutations in F9 Promoter

Mutations in the promoter region of the F9 gene often result in hemophilia B Leyden, which was first recognized in 1970 [18]. Individuals with hemophilia B Leyden have low FIX:C levels at birth, while their FIX:C levels rise rapidly at puberty, even to normal levels at adulthood [23]. More than 20 genetic mutations have been identified to be Leyden mutations [23]. These mutations distribute in a short region of the proximal promoter from c.-50 to c.-18, and cluster at three particular regions, including mutations in nucleotides c.-34 and c.-35, around nucleotide c.-49 and around nucleotide c.-19 [23]. Mutations in nucleotides c.-34 and c.-35 account for more than half of the cases of hemophilia B Leyden [9]. Depending on the mutations, some individuals initially exhibit severe hemophilia B, whereas others have a milder phenotype [16][24].
The mechanism of a progressive rise in the FIX:C level was originally thought to be related to the androgen receptors, which bind to the androgen-response element (ARE) binding site in the F9 promoter to regulate gene transcription [25]. However, the ARE binding site is from c.-65 to c.-51 [16][25], which does not overlap with the site of Leyden mutations. Later, three transcription factor binding sites were identified in the promoter region with hemophilia B Leyden mutations, including hepatic nuclear factor 4α (HNF4α), CCAAT/enhancer-binding protein (C/EBP), and HNF6 [26][27]. A transgenic mice model of hemophilia B Leyden demonstrated that growth hormone (GH) was directly responsible for the puberty onset recovery of FIX production, which indicated a critical role of GH signal transduction in Leyden mutations [28]. It remains elusive how GH regulates the transcription factors.
Different from hemophilia B Leyden, the mutation at c.-55 in the promoter region was reported to cause hemophilia B Brandenberg, which has a stable and low FIX:C level throughout life [29]. It remains unclear the binding of which transcriptional factor is affected by the mutations. Additionally, the phenotype of several mutations at the F9 promoter has not been established [16].

3.1.2. Mutations in Introns

In the F9 database, 226 patients had been reported with point mutations in the introns, accounting for 6.08% of the total patients (Table 2). Most of the intron point mutations were near the splice site (within 25 bp), and deep intron mutations were rarely reported in hemophilia B [9][16]. It has been reported that a mutation (c.392-569C>A) lies deeper in intron 4 of F9 with a severe phenotype, however, the variant has not been validated as causing the disorder [9]. Point mutations in the intron usually lead to aberrant splicing, which causes deletion or insertion in the mRNA sequence and consequently affects the expression of the functional protein. According to the F9 database, most hemophilia B patients with intron mutations show severe to moderate phenotypes [16], which is consistent with this mechanism. the researchers noticed a mutation of c.520+13A>G in intron 5, with which most of the patients varied from moderate to mild phenotypes [16]. The differences suggest that this mutation may interfere with alternative splicing to various extents in different patients, and there should be a certain level of normal splicing.

3.1.3. Mutations in 3′UTR

Twenty-two hemophilia B cases were reported with point mutations in 3′UTR [16]. The most reported mutation was c.2545A>G, with severe or moderate phenotypes. It had been proposed that this mutation leads to activation of a cryptic splice site that bypasses the polyadenylation signal, presumably destabilizing the mRNA or altering the splicing of the previous intron [30]. However, further experimental data are needed to support this proposition.

3.2. Point Mutations in Coding Region

Of the 1094 unique mutations in the F9 database, 689 point mutations have been retrieved in the coding region. These mutations cover 336 residues of 461 residues in the FIX precursor, and can cause silent, nonsense, and missense mutations.

3.2.1. Silent Mutations

Silent mutation is also called synonymous mutation, which alters a nucleotide but not the encoded amino acid. The majority of silent mutations in the F9 gene appear neutral clinically, while some could influence protein production due to aberrant splicing, mRNA instability, or abnormal translation [31]. Sixteen unique silent mutations have been retrieved in 46 patients with severe to mild hemophilia B in the F9 database [16], however, the underlying deleterious mechanisms have not been completely understood. Among these, several mutations near the end of exons have been proposed to cause a pathogenic effect at the stage of splicing control [9]. Exon-trap analysis showed that a case with c.87A>G (p.Thr29Thr) mutation resulted in nearly complete (99.1%) aberrant splicing (r.83–88del) [19]. The aberrant F9 mRNA was translated into a mutant FIX (p.Cys28–Val30delinsPhe) with an in-frame mutation at the signal peptide cleavage site, which was abnormally retained in the ER and not secreted to the extracellular. A small amount (0.9%) of mutant F9 r.87A>G translating into wildtype (WT) was also observed. Several cases with mutation c.459G>A (p.Val153Val) showed mild hemophilia B [32], and this mutation may impede translation, affect the protein conformation of FIX, and result in decreased extracellular protein level [33].

3.2.2. Nonsense Mutations and Ribosome Readthrough

Nonsense mutations account for about 11% of point mutations, and usually cause severe hemophilia B. Individuals with nonsense mutations have increased risk of inhibitor development [9]. the researchers noticed, however, a few patients with moderate or mild phenotypes [16], suggesting that spontaneous ribosome readthrough may occur with some nonsense mutations. Plasma from hemophilia B patients with the p.Arg294* and p.Arg298* mutations revealed traces of full-length FIX [34]. The in vitro expression also demonstrated a detectable level of secreted full-length FIX antigen for p.Arg162*, p.Arg294*, and p.Arg298* mutations [34]. A drug-induced readthrough model proposed for two mechanisms of the functional rescue: (1) prevalent reinsertion of the authentic residue (tryptophan), reverting the nonsense effects for the p.Trp240* and (2) gain-of-function for the p.Arg384* probably by readthrough-mediated missense variant (p.R384W) [35]. The amino acid substitutions in the ribosome readthrough depend on combinations of favorable FIX mRNA sequence and protein features. Ribosome readthrough in nonsense mutations that enable a low level of protein production has impacts on both disease severity and the likelihood of inhibitor development [35].

3.2.3. Missense Mutations in Signal Peptide and Propeptide

The signal peptide and propeptide are regulatory sequences, which are cleaved off in mature FIX. The researchers study showed that missense mutations in the signal peptide caused FIX deficiency by interfering with FIX’s co-translational translocation to ER, or signal peptide cleavage [8]. Mutations in the hydrophobic region of the signal peptide, such as p.Ile17Asn, p.Leu20Ser, p.Leu23Pro, and p.Leu24Pro, disrupt co-translational translocation to ER (Figure 2, step ②), and thus lead to dysfunction of FIX secretion. On the other hand, mutations in the signal peptidase recognition site, such as p.Ala26Asp and p.Cys28Arg/Tyr/Trp, interfered with signal peptide cleavage (Figure 2, step ④), resulting in a longer propeptide that in turn affected FIX secretion (p.Ala26Asp), expression (p.Cys28Arg/Tyr/Trp), or γ-carboxylation of the Gla domain (Figure 2, step ⑤; p.Ala26Asp and p.Cys28Arg/Tyr/Trp).
Figure 2. Schematic diagram of the FIX protein synthesis in liver cells. FIX protein synthesis is initiated in the cytoplasm (①), when the N-terminal signal peptide is synthesized, the signal recognition particle (SRP) recognizes the nascent signal peptide and stops the translation of FIX (②). Directed by SRP, the translation complex is translocated from the cytoplasm to the endoplasmic reticulum (ER) membrane (②), then the ribosome restarts the translation and the nascent polypeptide of FIX is co-translationally translocated into the ER lumen of liver cells (③). At the same time, the signal peptide is cleaved by signal peptidase in the ER lumen side (④). In the ER lumen, the propeptide of FIX directs the γ-carboxylation of glutamate residues in the Gla domain of FIX by an ER integral membrane protein, γ-glutamyl carboxylase (GGCX) (⑤). The fully γ-carboxylated FIX is transported to the Golgi apparatus by membrane coated vesicles (⑥), then the propeptide is cleaved by propeptidase (PACE/Furin) to generate mature FIX in the Golgi apparatus (⑦). The mature FIX is secreted into the blood (⑧). During FIX processing in the ER and Golgi apparatus, multiple post-translational modifications are added, such as N-linked glycosylation, O-linked glycosylation, and β-hydroxylation.
The subdomain of propeptide can be sub-divided into two elements: the GGCX recognition site and the propeptidase recognition site [36]. A study showed that propeptide mutations caused FIX deficiency via several different mechanisms [8]. In the GGCX recognition site, the mutation p.Val30Ile decreased the protein expression, p.Ala37Asp results in un-carboxylated Gla domain (Figure 2, step ⑤), p.Ala37Thr mainly decreases the γ-carboxylation efficiency, and p.Ala37Val mainly affects protein secretion. Mutations in propeptidase recognition site, such as p.Arg43Gln, p.Arg43Trp, p.Arg46Ser, lead to an uncleaved propeptide in mature FIX (Figure 2, step ⑦) that interferes with the binding of Gla domain to phospholipid membrane [37][38][39]. With the use of a conformation specific antibody to detect the calcium-stabilized Gla domain, the uncleaved propeptide was found to disrupt the structure of Gla domain [8].

3.2.4. Missense Mutations in Gla Domain

The Gla domain is involved in the FIXa binding to the phospholipids membrane, to TF in the TF/FVIIa complex, and to the C2 domain of FVIIIa [40][41], all of which are important to the full enzymatic activity of FIXa. In hemophilia B patients, naturally occurring point mutations are widely distributed in the Gla domain of FIX. Of the 12 glutamate residues, point mutations in nine residues have been reported in hemophilia B patients, and most of them showed severe bleeding phenotype [16]. Based on the structure of FIX Gla domain [42], these mutations should lead to destabilization of the ω-loop by disrupting its Ca2+ ion binding (Figure 3A). Most mutations in other residues at the ω-loop may also disturb the structure of this loop. For example, Asn48 is a structurally important residue for ω-loop, as its side chain forms hydrogen bonds with Gla54 and Gla73 and it is a ligand for a Ca2+ ion [42]. However, Lys51 is a surface-exposed residue and its side chain does not have a structural role in stabilizing the Gla domain. It has been proposed that this residue participates in binding the phosphate group of phosphatidylserine [43] and the collagen IV [44][45]. Additionally, Phe55, Phe71, and Arg75 in the Gla domain may be at the FVIIIa binding surface [42]. Thus, point mutations in these residues should affect the interaction between FIXa and FVIIIa. In summary, point mutations in the Gla domain disrupt the structural integrity of this region and affect the function of FIXa by weakening its interaction with the phospholipids membrane, TF, FVIIIa, or (and) collagen IV.
Figure 3. Structural model of human FIXa. (A) Overview of human FIXa’s structural model. The UniProt accession number of human FIX protein is P00740. The model is constructed in the following ways. The overall architecture is generated by Alphafold prediction [46]. Next, three partial human crystal structures, Gla domain (PDB: 1NL0) [42], EGF1 domain (PDB: 1EDM) [47], and combining EGF2-SP domain (PDB: 2WPH) [48] are superimposed onto the Alphafold model and a porcine FIXa crystal structure (PDB: 1PFX) [49] is superimposed to correct the inter-domain orientation between heavy and light chains. These superimposed crystal structures are combined to generate the final model. The Gla domain, EGF domains, SP domain, and linker sequence are colored in pink, blue, red, and grey, respectively. The Ca2+ ions are shown in the green sphere, and disulfide bonds in the green bars. The predicted interaction interfaces in FIXa with FVIIIa, with TF/FVIIa, and with membrane phospholipid are indicated by dashed curves (left) or dashed circles (right). The ω-loop in the Gla domain is also indicated by a dashed circle (right). (B) Structural model of human FIXa’s SP domain. Subdomain 1 and subdomain 2 are colored in light red and dark red, respectively. The active site cleft is formed between the two subdomains and side chains of the catalytic triad (His267, Asp315, and Ser415) are shown. These figures are generated with CCP 4 mg [50].

3.2.5. Missense Mutations in EGF1 and EGF2 Domains

Disulfide bonds maintain the structural integrity of the EGF domains (Figure 3A). Missense mutations of the cysteines break the disulfide bonds and cause a severe bleeding phenotype [16]. These cysteine mutations in hemophilia B patients are associated with reduced FIX antigen level, suggesting that they destabilize the FIX [16]. Besides the disulfide bonds, Ca2+ ion binding to the EGF1 domain is essential for stabilizing its conformation (Figure 3A) and for the assembly of the Xase complex on the phospholipid surface. Asp93, Gln96, and Asp110 in the EGF1 domain are designated for Ca2+ ion binding [47]. Missense hemophilic mutations in these residues [16][51][52] may disturb the stability of EGF1 domain, which serves to correctly position the SP domain for optimal interaction with FVIIIa [53].
Generating the full enzymatic activity for FIXa requires its binding to FVIIIa. Several hemophilic mutations in EGF domains may interfere with FIXa binding to FVIIIa [41][21]. A model of the Xase complex suggested that the conserved residues, Ile112, Tyr115, and Trp118, in the EGF1 domain, and Ile136, Asn138, and Arg140 in the EGF2 domain contribute to FVIIIa binding [49]. However, mutations in the EGF2 domain mainly affect FIXa binding to FVIIIa by hindering the interaction of FIXa’s SP domain with FVIIIa [53]. Additionally, hemophilia B patients with missense mutations in residues Ile136 and Val153 of the EGF2 domain may disrupt the interaction of FIXa with the activated platelet surface and the assembly of the Xase complex on activated platelets.
In the extrinsic coagulation pathway, activation of FIX is triggered by its interaction with the TF/FVIIa complex. A study showed that FIX are barely activated in hemophilia B patients with p.Gly94Arg and p.Gly94Val mutations that disrupt the interaction of FIX with TF/FVIIa complex [54], indicating that the EGF1 domain is essential for this interaction. In a binding model of FIX/TF/FVIIa, Asp95, Glu98, Ser99, Asn104, Phe123, Asn127, and Glu129 on the surface of the EGF1 domain were proposed to be the key determinants for FIX binding to TF [40] (Figure 3A). Consistent with this model, numerous missense mutations in these residues have been reported to cause hemophilia B [16]. Experimental evidence, however, is required to establish the role of these residues in TF binding.

3.2.6. Missense Mutations at Cleavage Site of Activation Peptide

More than 300 hemophilia B patients in the F9 database have been reported with mutations at the cleavage site of activation peptide, namely at residues Arg191 or Arg226 [16][55]. However, hemophilia B patients are rarely reported to have mutations in the other residues of the activation peptide, and only seldom have polymorphisms been retrieved. Removal of the activation peptide requires cleavages at both the Arg191 and Arg226 site, and the missense mutations disrupt these cleavages [55]. Seminal studies showed that the cleavage only at Arg191 resulted in the loss of FIXa catalytic activity [56][57], whereas the cleavage only at Arg226 retains the catalytic activity but results in suboptimal binding to FVIIIa [58][55]. Consistently, most patients with missense mutations at Arg191 are associated with a moderate or mild bleeding tendency [16][59][60][61], whereas those at Arg226 have a severe bleeding phenotype [16][62][63][64]. In contrast, the p.Arg226Lys mutation that retains a positively charged residue does not appear to cause hemophilia B, as the variant does not hinder the release of the activation peptide [55].
Patients with mutations at Arg191 and Arg226 have different FIX antigen levels. Mutations at Arg226 residues are associated with normal or increased FIX levels, whereas Arg191 mutations are characterized by normally or modestly reduced antigen levels [55]. These observations show the detrimental effects of Arg191 mutations on the protein folding, secretion, or scavenging processes [6], all of which contribute to decreased antigen levels in the FIX. In turn, these features shape the bleeding phenotypes of patients, and produce the graded moderate to mild bleeding severity in hemophilia B patients with the Arg191Cys>Leu>Pro>His mutations [55].

3.2.7. Missense Mutations in SP Domain

Among the hemophilia B patients with missense mutations, more than 55% have missense mutations located in the SP domain of FIX [9][16], emphasizing the importance of this domain. Cysteine residues involved in disulfide bond formation in the SP domain are important for stabilizing the protein folding (Figure 3), and missense mutations in these residues cause severe hemophilia B. The SP subdomain 1 contains a high affinity Ca2+ ion binding site (277–311 aa) at a surface loop [49] (Figure 3). Mutations in Arg294, Arg298, and Asn310 of the Ca2+ ion binding loop show significantly decreased FIX antigen levels [16][65][66][67], implying that the calcium loop affects the stability of the SP domain.
Impaired interaction with FVIIIa is another mechanism causing hemophilia B for missense mutations in the SP domain, especially those in subdomain 2 [16]. The 378-helix in SP subdomain 2 was thought to bind to FVIIIa [41] (Figure 3A). All known sequences from different species in this surface-exposed helix of FIXa are identical, and missense mutations in eight of the nine residues in this region cause hemophilia B [68], because mutations in this helix reduce FIXa’s affinity to FVIIIa. In addition, residues Lys339 in 339-helix and Asn392 were proposed to bind the A2 subunit of FVIIIa [49]. Subdomain-2 also contains an autolysis loop (356–369 aa), and mutations in this loop result in diminished binding of FIXa to FVIIIa. For example, mutation at Lys362 results in a substantial reduction in the rate of FX activation in the presence and absence of FVIIIa [69].
Additionally, the cleft between both SP subdomains forms the active site pocket that contain the catalytic triad of His267, Asp315, and Ser411 [49] (Figure 3B). Hemophilia B associated missense mutations in and around the active site pocket impairs the active site formation or substrate recognition [16].

References

  1. Staber, J.; Croteau, S.E.; Davis, J.; Grabowski, E.F.; Kouides, P.; Sidonio, R.F., Jr. The spectrum of bleeding in women and girls with haemophilia B. Haemophilia 2017, 24, 180–185.
  2. Biggs, R.; Douglas, A.S.; Macfarlane, R.G.; Dacie, J.V.; Pitney, W.R.; Merskey. Christmas disease: A condition previously mistaken for haemophilia. Br. Med. J. 1952, 2, 1378–1382.
  3. Sidonio, R.F., Jr.; Malec, L. Hemophilia B (Factor IX Deficiency). Hematol. Oncol. Clin. N. Am. 2021, 35, 1143–1155.
  4. Peyvandi, F.; Garagiola, I.; Young, G. The past and future of haemophilia: Diagnosis, treatments, and its complications. Lancet 2016, 388, 187–197.
  5. White, G.C., 2nd; Rosendaal, F.; Aledort, L.M.; Lusher, J.M.; Rothschild, C.; Ingerslev, J. Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb. Haemost. 2001, 85, 560.
  6. Stafford, D.W. Extravascular FIX and coagulation. Thromb. J. 2016, 14, 35.
  7. Castaman, G.; Matino, D. Hemophilia A and B: Molecular and clinical similarities and differences. Haematologica 2019, 104, 1702–1709.
  8. Gao, W.; Xu, Y.; Liu, H.; Gao, M.; Cao, Q.; Wang, Y.; Cui, L.; Huang, R.; Shen, Y.; Li, S.; et al. Characterization of missense mutations in the signal peptide and propeptide of FIX in hemophilia B by a cell-based assay. Blood Adv. 2020, 4, 3659–3667.
  9. Goodeve, A.C. Hemophilia B: Molecular pathogenesis and mutation analysis. J. Thromb. Haemost. 2015, 13, 1184–1195.
  10. Choo, K.H.; Gould, K.G.; Rees, D.J.; Brownlee, G.G. Molecular cloning of the gene for human anti-haemophilic factor IX. Nature 1982, 299, 178–180.
  11. Kurachi, K.; Davie, E.W. Isolation and characterization of a cDNA coding for human factor IX. Proc. Natl. Acad. Sci. USA 1982, 79, 6461–6464.
  12. Chance, P.F.; Dyer, K.A.; Kurachi, K.; Yoshitake, S.; Ropers, H.H.; Wieacker, P.; Gartler, S.M. Regional localization of the human factor IX gene by molecular hybridization. Hum. Genet. 1983, 65, 207–208.
  13. Miller, C.H. The Clinical Genetics of Hemophilia B (Factor IX Deficiency). Appl. Clin. Genet. 2021, 14, 445–454.
  14. Yoshitake, S.; Schach, B.G.; Foster, D.C.; Davie, E.W.; Kurachi, K. Nucleotide sequence of the gene for human factor IX (antihemophilic factor B). Biochemistry 1985, 24, 3736–3750.
  15. Lillicrap, D. The molecular basis of haemophilia B. Haemophilia 1998, 4, 350–357.
  16. Rallapalli, P.M.; Kemball-Cook, G.; Tuddenham, E.G.; Gomez, K.; Perkins, S.J. An interactive mutation database for human coagulation factor IX provides novel insights into the phenotypes and genetics of hemophilia B. J. Thromb. Haemost. 2013, 11, 1329–1340.
  17. Harris, V.A.; Lin, W.; Perkins, S.J. Analysis of 272 Genetic Variants in the Upgraded Interactive FXI Web Database Reveals New Insights into FXI Deficiency. TH Open 2021, 5, e543–e556.
  18. Veltkamp, J.J.; Meilof, J.; Remmelts, H.G.; van der Vlerk, D.; Loeliger, E.A. Another genetic variant of haemophilia B: Haemophilia B Leyden. Scand. J. Haematol. 1970, 7, 82–90.
  19. Odaira, K.; Tamura, S.; Suzuki, N.; Kakihara, M.; Hattori, Y.; Tokoro, M.; Suzuki, S.; Takagi, A.; Katsumi, A.; Hayakawa, F.; et al. Apparent synonymous mutation F9 c.87A>G causes secretion failure by in-frame mutation with aberrant splicing. Thromb. Res. 2019, 179, 95–103.
  20. Green, P.M.; Bentley, D.R.; Mibashan, R.S.; Nilsson, I.M.; Giannelli, F. Molecular pathology of haemophilia B. EMBO J. 1989, 8, 1067–1072.
  21. Melendez-Aranda, L.; Jaloma-Cruz, A.R.; Pastor, N.; Romero-Prado, M.M.J. In silico analysis of missense mutations in exons 1-5 of the F9 gene that cause hemophilia B. BMC Bioinform. 2019, 20, 363.
  22. Meireles, M.R.; Bragatte, M.A.S.; Bandinelli, E.; Salzano, F.M.; Vieira, G.F. A new in silico approach to investigate molecular aspects of factor IX missense causative mutations and their impact on the hemophilia B severity. Hum. Mutat. 2019, 40, 706–715.
  23. Ahmed, S.Z.; O’Rourke, M.; Jenkins, V.; Regan, I.; Nolan, B. Progressive increase in FIX level in males with haemophilia B Leyden and c.35G > A mutation in early childhood not related to androgen effect. Br. J. Haematol. 2020, 189, e262–e265.
  24. Crossley, M.; Winship, P.R.; Austen, D.E.; Rizza, C.R.; Brownlee, G.G. A less severe form of Haemophilia B Leyden. Nucleic Acids Res. 1990, 18, 4633.
  25. Crossley, M.; Ludwig, M.; Stowell, K.M.; De Vos, P.; Olek, K.; Brownlee, G.G. Recovery from hemophilia B Leyden: An androgen-responsive element in the factor IX promoter. Science 1992, 257, 377–379.
  26. Funnell, A.P.; Crossley, M. Hemophilia B Leyden and once mysterious cis-regulatory mutations. Trends Genet. 2014, 30, 18–23.
  27. Funnell, A.P.; Wilson, M.D.; Ballester, B.; Mak, K.S.; Burdach, J.; Magan, N.; Pearson, R.C.; Lemaigre, F.P.; Stowell, K.M.; Odom, D.T.; et al. A CpG mutational hotspot in a ONECUT binding site accounts for the prevalent variant of hemophilia B Leyden. Am. J. Hum. Genet. 2013, 92, 460–467.
  28. Kurachi, S.; Huo, J.S.; Ameri, A.; Zhang, K.; Yoshizawa, A.C.; Kurachi, K. An age-related homeostasis mechanism is essential for spontaneous amelioration of hemophilia B Leyden. Proc. Natl. Acad. Sci. USA 2009, 106, 7921–7926.
  29. Heit, J.A.; Ketterling, R.P.; Zapata, R.E.; Ordonez, S.M.; Kasper, C.K.; Sommer, S.S. Haemophilia B Brandenberg-type promoter mutation. Haemophilia 1999, 5, 73–75.
  30. Vielhaber, E.; Jacobson, D.P.; Ketterling, R.P.; Liu, J.Z.; Sommer, S.S. A mutation in the 3′ untranslated region of the factor IX gene in four families with hemophilia B. Hum. Mol. Genet. 1993, 2, 1309–1310.
  31. Sauna, Z.E.; Kimchi-Sarfaty, C. Understanding the contribution of synonymous mutations to human disease. Nat. Rev. Genet. 2011, 12, 683–691.
  32. Knobe, K.E.; Sjorin, E.; Ljung, R.C. Why does the mutation G17736A/Val107Val (silent) in the F9 gene cause mild haemophilia B in five Swedish families? Haemophilia 2008, 14, 723–728.
  33. Simhadri, V.L.; Hamasaki-Katagiri, N.; Lin, B.C.; Hunt, R.; Jha, S.; Tseng, S.C.; Wu, A.; Bentley, A.A.; Zichel, R.; Lu, Q.; et al. Single synonymous mutation in factor IX alters protein properties and underlies haemophilia B. J. Med. Genet. 2017, 54, 338–345.
  34. Pinotti, M.; Caruso, P.; Canella, A.; Campioni, M.; Tagariello, G.; Castaman, G.; Giacomelli, S.; Belvini, D.; Bernardi, F. Ribosome readthrough accounts for secreted full-length factor IX in hemophilia B patients with nonsense mutations. Hum. Mutat. 2012, 33, 1373–1376.
  35. Branchini, A.; Ferrarese, M.; Campioni, M.; Castaman, G.; Mari, R.; Bernardi, F.; Pinotti, M. Specific factor IX mRNA and protein features favor drug-induced readthrough over recurrent nonsense mutations. Blood 2017, 129, 2303–2307.
  36. Hao, Z.; Jin, D.Y.; Stafford, D.W.; Tie, J.K. Vitamin K-dependent carboxylation of coagulation factors: Insights from a cell-based functional study. Haematologica 2020, 105, 2164–2173.
  37. Bentley, A.K.; Rees, D.J.; Rizza, C.; Brownlee, G.G. Defective propeptide processing of blood clotting factor IX caused by mutation of arginine to glutamine at position-4. Cell 1986, 45, 343–348.
  38. Ware, J.; Diuguid, D.L.; Liebman, H.A.; Rabiet, M.J.; Kasper, C.K.; Furie, B.C.; Furie, B.; Stafford, D.W. Factor IX San Dimas. Substitution of glutamine for Arg-4 in the propeptide leads to incomplete gamma-carboxylation and altered phospholipid binding properties. J. Biol. Chem. 1989, 264, 11401–11406.
  39. Huang, L.; Li, L.; Lin, S.; Chen, J.; Li, K.; Fan, D.; Jin, W.; Li, Y.; Yang, X.; Xiong, Y.; et al. Molecular analysis of 76 Chinese hemophilia B pedigrees and the identification of 10 novel mutations. Mol. Genet. Genom. Med. 2020, 8, e1482.
  40. Kirchhofer, D.; Lipari, M.T.; Moran, P.; Eigenbrot, C.; Kelley, R.F. The tissue factor region that interacts with substrates factor IX and Factor, X. Biochemistry 2000, 39, 7380–7387.
  41. Venkateswarlu, D. Structural insights into the interaction of blood coagulation co-factor VIIIa with factor IXa: A computational protein-protein docking and molecular dynamics refinement study. Biochem. Biophys. Res. Commun. 2014, 452, 408–414.
  42. Huang, M.; Furie, B.C.; Furie, B. Crystal structure of the calcium-stabilized human factor IX Gla domain bound to a conformation-specific anti-factor IX antibody. J. Biol. Chem. 2004, 279, 14338–14346.
  43. Huang, M.; Rigby, A.C.; Morelli, X.; Grant, M.A.; Huang, G.; Furie, B.; Seaton, B.; Furie, B.C. Structural basis of membrane binding by Gla domains of vitamin K-dependent proteins. Nat. Struct. Biol. 2003, 10, 751–756.
  44. Mann, D.M.; Stafford, K.A.; Poon, M.C.; Matino, D.; Stafford, D.W. The Function of extravascular coagulation factor IX in haemostasis. Haemophilia 2021, 27, 332–339.
  45. Cooley, B.; Broze, G.J., Jr.; Mann, D.M.; Lin, F.C.; Pedersen, L.G.; Stafford, D.W. Dysfunctional endogenous FIX impairs prophylaxis in a mouse hemophilia B model. Blood 2019, 133, 2445–2451.
  46. Jumper, J.; Evans, R.; Pritzel, A.; Green, T.; Figurnov, M.; Ronneberger, O.; Tunyasuvunakool, K.; Bates, R.; Zidek, A.; Potapenko, A.; et al. Highly accurate protein structure prediction with AlphaFold. Nature 2021, 596, 583–589.
  47. Rao, Z.; Handford, P.; Mayhew, M.; Knott, V.; Brownlee, G.G.; Stuart, D. The structure of a Ca(2+)-binding epidermal growth factor-like domain: Its role in protein-protein interactions. Cell 1995, 82, 131–141.
  48. Zogg, T.; Brandstetter, H. Structural basis of the cofactor- and substrate-assisted activation of human coagulation factor IXa. Structure 2009, 17, 1669–1678.
  49. Brandstetter, H.; Bauer, M.; Huber, R.; Lollar, P.; Bode, W. X-ray structure of clotting factor IXa: Active site and module structure related to Xase activity and hemophilia B. Proc. Natl. Acad. Sci. USA 1995, 92, 9796–9800.
  50. McNicholas, S.; Potterton, E.; Wilson, K.S.; Noble, M.E.M. Presenting your structures: The CCP4mg molecular-graphics software. Acta Crystallogr. Sect. D Biol. Crystallogr. 2011, 67, 386–394.
  51. Quadros, L.; Ghosh, K.; Shetty, S. Novel mutations in factor IX gene from western India with reference to their phenotypic and haplotypic attributes. J. Pediatr. Hematol. Oncol. 2009, 31, 157–160.
  52. Liu, J.Z.; Li, X.; Drost, J.; Thorland, E.C.; Liu, Q.; Lind, T.; Roberts, S.; Wang, H.Y.; Sommer, S.S. The human factor IX gene as germline mutagen test: Samples from Mainland China have the putatively endogenous pattern of mutation. Hum. Mutat. 2000, 16, 31–36.
  53. Schmidt, A.E.; Bajaj, S.P. Structure-function relationships in factor IX and factor IXa. Trends Cardiovasc. Med. 2003, 13, 39–45.
  54. Wu, P.C.; Hamaguchi, N.; Yu, Y.S.; Shen, M.C.; Lin, S.W. Hemophilia B with mutations at glycine-48 of factor IX exhibited delayed activation by the factor VIIa-tissue factor complex. Thromb. Haemost. 2000, 84, 626–634.
  55. Branchini, A.; Morfini, M.; Lunghi, B.; Belvini, D.; Radossi, P.; Bury, L.; Serino, M.L.; Giordano, P.; Cultrera, D.; Molinari, A.C.; et al. F9 missense mutations impairing factor IX activation are associated with pleiotropic plasma phenotypes. J. Thromb. Haemost. 2021, 20, 69–81.
  56. Zogg, T.; Brandstetter, H. Activation mechanisms of coagulation factor IX. Biol. Chem. 2009, 390, 391–400.
  57. Lenting, P.J.; ter Maat, H.; Clijsters, P.P.; Donath, M.J.; van Mourik, J.A.; Mertens, K. Cleavage at arginine 145 in human blood coagulation factor IX converts the zymogen into a factor VIII binding enzyme. J. Biol. Chem. 1995, 270, 14884–14890.
  58. Gailani, D.; Geng, Y.; Verhamme, I.; Sun, M.F.; Bajaj, S.P.; Messer, A.; Emsley, J. The mechanism underlying activation of factor IX by factor XIa. Thromb. Res. 2014, 133 (Suppl. 1), S48–S51.
  59. Diuguid, D.L.; Rabiet, M.J.; Furie, B.C.; Furie, B. Molecular defects of factor IX Chicago-2 (Arg 145----His) and prothrombin Madrid (Arg 271----cys): Arginine mutations that preclude zymogen activation. Blood 1989, 74, 193–200.
  60. Liddell, M.B.; Peake, I.R.; Taylor, S.A.; Lillicrap, D.P.; Giddings, J.C.; Bloom, A.L. Factor IX Cardiff: A variant factor IX protein that shows abnormal activation is caused by an arginine to cysteine substitution at position 145. Br. J. Haematol. 1989, 72, 556–560.
  61. Belvini, D.; Salviato, R.; Radossi, P.; Pierobon, F.; Mori, P.; Castaldo, G.; Tagariello, G. Molecular genotyping of the Italian cohort of patients with hemophilia B. Haematologica 2005, 90, 635–642.
  62. Huang, M.N.; Kasper, C.K.; Roberts, H.R.; Stafford, D.W.; High, K.A. Molecular defect in factor IXHilo, a hemophilia Bm variant: Arg----Gln at the carboxyterminal cleavage site of the activation peptide. Blood 1989, 73, 718–721.
  63. Usharani, P.; Warn-Cramer, B.J.; Kasper, C.K.; Bajaj, S.P. Characterization of three abnormal factor IX variants (Bm Lake Elsinore, Long Beach, and Los Angeles) of hemophilia-B. Evidence for defects affecting the latent catalytic site. J. Clin. Investig. 1985, 75, 76–83.
  64. Monroe, D.M.; McCord, D.M.; Huang, M.N.; High, K.A.; Lundblad, R.L.; Kasper, C.K.; Roberts, H.R. Functional consequences of an arginine180 to glutamine mutation in factor IX Hilo. Blood 1989, 73, 1540–1544.
  65. Radic, C.P.; Rossetti, L.C.; Abelleyro, M.M.; Candela, M.; Perez Bianco, R.; de Tezanos Pinto, M.; Larripa, I.B.; Goodeve, A.; De Brasi, C. Assessment of the F9 genotype-specific FIX inhibitor risks and characterisation of 10 novel severe F9 defects in the first molecular series of Argentinian patients with haemophilia B. Thromb. Haemost. 2013, 109, 24–33.
  66. Yu, T.; Dai, J.; Liu, H.; Ding, Q.; Lu, Y.; Wang, H.; Wang, X.; Fu, Q. Spectrum of F9 mutations in Chinese haemophilia B patients: Identification of 20 novel mutations. Pathology 2012, 44, 342–347.
  67. Weinmann, A.F.; Murphy, M.E.; Thompson, A.R. Consequences of factor IX mutations in 26 families with haemophilia B. Br. J. Haematol. 1998, 100, 58–61.
  68. Bajaj, S.P. Region of factor IXa protease domain that interacts with factor VIIIa: Analysis of select hemophilia B mutants. Thromb. Haemost. 1999, 82, 218–225.
  69. Mathur, A.; Zhong, D.; Sabharwal, A.K.; Smith, K.J.; Bajaj, S.P. Interaction of factor IXa with factor VIIIa. Effects of protease domain Ca2+ binding site, proteolysis in the autolysis loop, phospholipid, and factor X. J. Biol. Chem. 1997, 272, 23418–23426.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/)
Academic Video Service
Feedback